share_log

Biodexa Pharmaceuticals | EFFECT: Others

Biodexa Pharmaceuticals | EFFECT: Others

Biodexa Pharmaceuticals | EFFECT:其他
美股SEC公告 ·  08/20 06:04

Moomoo AI 已提取核心訊息

The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's Form F-1 has become effective as of August 19, 2024, at 4:30 P.M. This form is typically used by non-U.S. companies for registering securities for an initial public offering (IPO) in the United States. The effectiveness of the form indicates that Biodexa Pharmaceuticals has met all the necessary regulatory requirements to proceed with its IPO.
The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's Form F-1 has become effective as of August 19, 2024, at 4:30 P.M. This form is typically used by non-U.S. companies for registering securities for an initial public offering (IPO) in the United States. The effectiveness of the form indicates that Biodexa Pharmaceuticals has met all the necessary regulatory requirements to proceed with its IPO.
美國證券和交易委員會(SEC)宣佈,Biodexa製藥公司的F-1表格於2024年8月19日下午4點30分生效。該表格通常由非美國公司用於在美國註冊證券進行首次公開募股(IPO)。表格的生效表示Biodexa製藥公司已滿足所有必要的監管要求,可以繼續進行IPO。
美國證券和交易委員會(SEC)宣佈,Biodexa製藥公司的F-1表格於2024年8月19日下午4點30分生效。該表格通常由非美國公司用於在美國註冊證券進行首次公開募股(IPO)。表格的生效表示Biodexa製藥公司已滿足所有必要的監管要求,可以繼續進行IPO。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息